MarginsXMarginsX
Home › Markets › Health Care › LEGN

Legend Biotech Corporation (LEGN)

LEGN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$15.99
-8.63% on the day
Market cap
$3.1B
Mid cap
Revenue · 2025
$1.0B
+64.0% on 2024
Net income · 2025
-$296.8M
-28.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/0001801198-26-000008-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerLEGN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001801198
SEC industry codePharmaceutical Preparations
Incorporated inCayman Islands

Financials · 2025

LineValue
Revenue$1.0B
Net income-$296.8M
Operating income-$136.5M
Net margin-28.8%
Operating margin-13.3%
Revenue growth+64.0%
Cash$901.9M
Total assets$1.7B
P/E (computed)Net income was not positive
P/S (computed)3.0×

Warning signs

Cash runway
108.0 months
$901.9M cash at December 31, 2025
Share count, 1 year
+0.7%
2024-12-31 to 2025-12-31 · +12.0% over 3 years
Going-concern doubt
No
20-F filed March 10, 2026
Insider net buying, 12 months
-$308K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Our prior losses and any future losses have had and will continue to have an adverse effect on our working capital, our ability to fund the development of our product candidates and our ability to achieve and maintain profitability and the performance of our common shares and may in the future raise substantial doubt about our ability to continue as a going concern."
20-F 2026-03-10
Cash and burn$901.9M cash; operating cash flow -$25.1M a quarter.Report 2025-12-31
Shares outstanding184,943,185 (2025-12-31); 183,649,158 a year earlier; 165,067,240 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-06-18
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-03-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $308K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$1.0B-$296.8M-$100.2M$901.9M$319.1M$1.0B20-F 2026-03-10
FY 2024
2024-12-31
$627.2M-$177.0M-$144.0M$286.7M$250.0M$627.2M20-F 2025-03-11
FY 2023
2023-12-31
$285.1M-$518.3M-$393.3M$1.3B$250.0M$285.1M20-F 2025-03-11
FY 2022
2022-12-31
$117.0M-$446.3M-$201.3M$786.0M$250.0M$117.0M20-F 2025-03-11
FY 2021
2021-12-31
$68.8M-$403.6M-$198.5M$688.9M$119.7M$68.8M20-F 2024-03-19
FY 2020
2020-12-31
$75.0M-$266.4M-$223.0M$455.7MNo debt tags$75.0M20-F 2023-03-30
FY 2019
2019-12-31
$60.0M-$101.6M-$83.1M$83.4MNo debt tags$60.0M20-F/A 2023-02-17
FY 2018
2018-12-31
$49.1M-$2.8M$307.7M$210.2MNo debt tags$49.1M20-F 2021-04-02

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-06-18
Latest annual report20-F2026-03-10
Latest quarterly / interim6-K2026-11-10

Source: SEC EDGAR submissions feed, 388 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-25.2%
1 month-2.1%
3 months-13.7%
Year to date-19.5%
1 year-43.6%
From 52-week high-51.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
DYNDyne Therapeutics Inc.$16.70-2.68%$3.1B
BHCBausch Health Companies Inc.$8.42+0.84%$3.2B
XERSXeris Biopharma Holdings Inc.$16.70+0.24%$3.1B
TLXTelix Pharmaceuticals Limited$8.92-3.36%$3.0B
ACADACADIA Pharmaceuticals Inc.$18.67-0.43%$3.2B
IDYAIDEAYA Biosciences Inc.$30.36-4.62%$2.9B
VCREVicore Pharma Holding AB$10.16-1.93%$2.9B
VRDNViridian Therapeutics Inc.$29.80-3.47%$3.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier